Biogen looks to expand neuro pipeline via C4, Skyhawk deals

A pair of deals announced Friday leaves Biogen Inc. (NASDAQ:BIIB) poised to expand the druggable space of its neurology pipeline. Biogen...

Biotech Celgene inks $60M deal with newcomer Skyhawk to develop RNA drugs for ALS, Huntington’s

Under the deal, Celgene received the exclusive option to license up to five drug candidates born out of Skyhawk’s development platform

Disney, Family Offices Back Second Bio Startup from Tech Entrepreneur Haney

To launch his first biotech startup, Dragonfly Therapeutics, Bill Haney went to private family offices, including one linked to the...

Joining forces with Skyhawk, C4 Therapeutics, Biogen buys more shots on goal on SMA, Alzheimer’s

In twin deals an­nounced on Fri­day, Bio­gen $BI­IB is ty­ing up with Sky­hawk Ther­a­peu­tics

The new serial entrepreneur in the biotech arena launches another upstart looking to drug RNA

Af­ter a life­time of en­tre­pre­neur­ship, Bill Haney has dis­cov­ered how much fun it can be to set up new biotechs.

Skyhawk Announces Strategic Collaboration with Celgene to Discover and Develop Novel mRNA Splicing

Skyhawk and Celgene enter into a five-year strategic collaboration.

Skyhawk, copying Dragonfly model, gets cash for RNA R&D

Tim Disney—the great-nephew of Walt Disney—is among those who have signed term sheets.